Prostate cancer is the third most common cause of death from cancer in males, associated with an estimated 27,350 deaths and 234,460 new cases in 2006. In 2004, two landmark trialsTAX 327 and Southwest Onology Group (SWOG) 9916[1,2]led to the US Food and Drug Administration (FDA) approval of docetaxel(Drug information on docetaxel) (Taxotere) and prednisone(Drug information on prednisone) as first-line therapy for patients with metastatic, progressive prostate cancer. However, treatment continues to be palliative, and survival benefits are modest. Therefore, there is great interest in novel therapies for this disease. Our ever more detailed understanding of pathways involved in the development and progression of cancer has resulted in the identification of a number of new targets for drug development. Fortunately, several different classes of drugs are in simultaneous development, a result of varied approaches to different parts of the tumor-progression cascade.Berthold and Moore provide an excellent overview of the major classes of agents currently being evaluated in clinical trials, including inhibitors of the epidermal growth factor receptor, antiangiogenic therapies (bevacizumab [Avastin] and others), vaccines, agents promoting cell differentiation and inhibiting cell proliferation (DN-101, or high-dose calcitriol(Drug information on calcitriol)), endothelin-receptor antagonists (atrasentan [Xinlay]), monoclonal antibodies, antisense oligonucleotides, and novel cytotoxic agents such as epothilones and satraplatin. The most promising phase III trials are evaluating docetaxel plus prednisone in combination with atrasentan, bevacizumab(Drug information on bevacizumab), DN-101, and a variety of vaccine strategies, to address the important question of whether these therapies will result in improved survival or time to progression compared with the current standard of care.
Areas of Investigation
The primary and most significant site of metastases in prostate cancer is bone. Therefore, agents targeting both primary prostate cancer and its bone metastases would be optimal. Endothelins and their receptors are expressed in endothelial cells and are overexpressed in prostate cancer cells and in bone metastases.[4,5] Receptor activation leads to tumor proliferation, migration, angiogenesis, and osteogenesis.[6-9] As Berthold and Moore note, trials of the endothelin inhibitor atrasentan have shown promise, although we are still waiting for the results of the phase III trial of atrasentan in combination with docetaxel and prednisone.
Agents inhibiting angiogenesis and the angiogenic cascade are also under active investigation. Thalidomide(Drug information on thalidomide) (Thalomid) has shown significant activity in combination with docetaxel in a phase II trial, and the combination of thalidomide, bevacizumab, and docetaxel also appears promising. The monoclonal antibody bevacizumab targets and inactivates vascular endothelial growth factor (VEGF)-A. The Cancer and Leukemia Group B (CALGB) 90006 trial evaluated bevacizumab together with estramustine(Drug information on estramustine) (Emcyt) and docetaxel in 79 patients with androgen-independent prostate cancer (AIPC). In this trial, 53 of those with measurable disease experienced a partial response, with 65% of 20 evalauble patients showing a > 50% decline in prostate-specific antigen (PSA) levels. CALGB 90401 is a randomized, phase III trial evaluating bevacizumab with docetaxel and prednisone vs docetaxel/prednisone in patients with AIPC. Overall survival is the primary endpoint in this trial.The fact that VEGF and its receptor have also been found to be expressed in prostate cancer cells provides an additional rationale for using these agents in prostate cancer. In this regard, receptor tyrosine kinase (RTK) inhibitors such as sorafenib(Drug information on sorafenib) (Nexavar), sunitinib (Sutent), and AZD2171all in phase II developmentcould prove to be especially efficacious. Other kinase inhibitors, including those with activity against MEK and Src/Abl, are also in development for the treatment of solid tumors. Our concern with some of these agents is the discord between PSA change and tumor burden.
Novel combination therapies aimed at inhibiting multiple targets in a single pathway or separate signaling pathways, with or without docetaxel and/or prednisone, are also worth investigating. Considering that downstream signaling of RTKs acts through the Ras/MEK/ERK pathway, a combination consisting of docetaxel, an RTK, and a MEK inhibitor may be reasonable. In addition, the endothelin receptor is downstream of the Ras/MEK/ERK cascade, and a MEK inhibitor has been found to be active against the endothelin receptor.Histone deacetylase inhibitors (HDACi) inhibit proliferation and induce apoptosis in a variety of cell types. In addition, these compounds have antiangiogenic properties. A combination of inhibitors of histone deacetylase and RTKs with and without docetaxel and/or prednisone may be active in this setting. The HDACi suberoylanilide hydroxamic acid (SAHA) has been shown to be active in preclinical studies of prostate cancer. In a murine xenograft model of prostate cancer, the combination of inhibitors against peroxisome proliferator-activated receptor gamma (PPARgamma) and valproic acid (an HDACi) were active.